Featured Slider

Our authors of the month evaluated an experimental treatment for human prion disease, based on a fully humanised monoclonal antibody (PRN100) addressed against the cellular prion protein (PrP).

Our authors of the month conducted this retrospective case-control study in order to investigate the association of AD with the risk of COVID-19 infection (adjusted for comorbidities and sociodemographic factors).

EAN President, Claudio Bassetti on recent and upcoming collaborations with National Neurological Societies and their vital importance to the European neurology landscape.

Our paper of the month describes a study led by Stanford University researchers, which now provides a mechanistic basis for how EBV infection can trigger the patient’s immune cells to attack self-tissue within the CNS.

Our authors of the month conducted a longitudinal, multi-modal brain imaging study using the UK biobank, whereby participants had already been scanned before getting infected with SARS-CoV-2, offering a unique resource to elucidate these questions.

The European Academy of Neurology condemns the military invasion of Ukraine ordered by the Russian government and the violation of international law.

Our authors of the month conducted a systematic retrospective analysis of 150 lumbar punctures in 127 patients with PCR-proven COVID-19 and neurological symptoms seen at 17 European university centres.

Our research paper of the month for March is a cohort study exploring the risk of developing multiple sclerosis (MS) after infection with Epstein-Barr virus (EBV).

The International Classification of Diseases 11 (ICD 11), maintained by the WHO and distributed globally, came into effect on 1 January 2022. The most notable change in the new set of classifications is that stroke has been reclassified as a neurological disorder, having previously been classed as a circulatory system disease for several decades.

Our authors of the month conducted a systematic review and meta-analysis in order to summarise the frequency of neurologic manifestations in patients with COVID-19 and to investigate the association of these manifestations with disease severity and mortality.

For February we have selected Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomized, placebo-controlled trial.

With 2022 named European Year of Youth by the European Commission, the EAN President Elect takes a look at all the initiatives EAN offers to support young neurologists

EAN Programme Committee Chair, Tony Marson, on abstract submission, registration and the preliminary programme for EAN 2022.

Our research paper of the month is a multicentre, randomised and double-blind phase 2 study with a futility design, exploring the efficacy and the safety of guanabenz in patients with probable or definite amyotrophic lateral sclerosis (ALS).

Our authors of the month conducted a systematic review of SARS-CoV-2-associated deaths in Hamburg, Germany, from March to December 2020, using conventional autopsy, ultrasound-guided minimally invasive autopsy, postmortem computed tomography (PMCT) and medical record review.